Journal: Biomarker Research

Article Title: Circulating bone morphogenetic protein 8A is a novel biomarker to predict advanced liver fibrosis

doi: 10.1186/s40364-023-00489-2

Figure Lengend Snippet: Increased hepatic Bmp8a expression in BDL mice. A Representative images of H&E and Sirius Red staining. Evaluation of the fibrosis stage (upper panel) and quantification of Sirius Red expressed as % of stained area (lower panel). B Hepatic mRNA levels of Col1a1, Acta2 and Serpin1 determined by RT-qPCR and normalized to 36b4 gene expression. C Hepatic mRNA levels of Bmp8a determined by RT-qPCR and normalized to 36b4 gene expression. D , E , F and G Correlation of matched Bmp8a mRNA expression with fibrosis stage, Col1a1, Acta2 and Serpin1 mRNA expression, respectively. Experimental conditions: mice with either BDL or sham operation and sacrificed 28 days after operation ( N = 7 animals per group). BDL, bile duct ligation. Data are expressed as fold increase relative to control condition (sham group, 1) and presented as mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.005 and **** p < 0.0001, BDL vs. Sham

Article Snippet: BMP8A concentration in serum samples was determined using the human BMP8A ELISA kit (CSB-EL002745HU, Cusabio Technology LLC, Hubei, China) for human samples and mouse BMP8A ELISA kit (MBS7205421, MyBioSource Inc., San Diego, CA, USA) for samples from mice, following manufacturer’s indications.

Techniques: Expressing, Staining, Quantitative RT-PCR, Gene Expression, Ligation, Control

Journal: Biomarker Research

Article Title: Circulating bone morphogenetic protein 8A is a novel biomarker to predict advanced liver fibrosis

doi: 10.1186/s40364-023-00489-2

Figure Lengend Snippet: Hepatic Bmp8a expression is upregulated in NAFLD mice. A Representative images of H&E and Sirius Red staining. NAFLD activity score evaluation (upper panel) and quantification of Sirius Red expressed as % of stained area (lower panel). B Hepatic mRNA levels of Col1a1 and Serpin1 determined by RT-qPCR and normalized to 36b4 gene expression. C Hepatic mRNA levels of Bmp8a determined by RT-qPCR and normalized to 36b4 gene expression. D , E , F and G Correlation of matched Bmp8a mRNA expression with NAFLD activity score, fibrosis stage, Col1a1 and Serpin1 mRNA expression, respectively. Experimental conditions: mice fed with HFD or CHD (control group) for 16 weeks ( N = 5 animals per group). NAFLD, nonalcoholic fatty liver disease. Data are expressed as fold increase relative to control condition (CHD group, 1) and presented as mean ± SEM. * p < 0.05, ** p < 0.01 and *** p < 0.005, HFD vs. CHD

Article Snippet: BMP8A concentration in serum samples was determined using the human BMP8A ELISA kit (CSB-EL002745HU, Cusabio Technology LLC, Hubei, China) for human samples and mouse BMP8A ELISA kit (MBS7205421, MyBioSource Inc., San Diego, CA, USA) for samples from mice, following manufacturer’s indications.

Techniques: Expressing, Staining, Activity Assay, Quantitative RT-PCR, Gene Expression, Control

Journal: Biomarker Research

Article Title: Circulating bone morphogenetic protein 8A is a novel biomarker to predict advanced liver fibrosis

doi: 10.1186/s40364-023-00489-2

Figure Lengend Snippet: TGFβ induces BMP8A expression and secretion in LX2 HSCs and in Huh7 cells. A Representative phase-contrast images. B mRNA levels of COL1A1 and TGFB1 determined by RT-qPCR and normalized to 36B4 gene expression. C Representative blot of cell lysates with αSMA and COL1A1 antibodies. Ponceau staining as loading control. D Representative phase-contrast images. E mRNA levels of BMP8a determined by RT-qPCR and normalized to 36B4 gene expression. F Representative blot of CM with BMP8A antibody. Ponceau staining as loading control. As positive control ( +), HEK293 whole cell lysate was used. Experimental conditions: LX2 or Huh7 cells treated with TGFβ 10 ng/ml for 24 h ( n ≥ 3 independent experiments performed by duplicate). Huh7, human hepatocyte-derived cell line. LX2, human HSC line. CM, cultured media. Data are expressed as fold increase relative to control condition (C, 1) and presented as mean ± SEM. * p < 0.05, ** p < 0.01 and **** p < 0.0001 TGFβ vs. C

Article Snippet: BMP8A concentration in serum samples was determined using the human BMP8A ELISA kit (CSB-EL002745HU, Cusabio Technology LLC, Hubei, China) for human samples and mouse BMP8A ELISA kit (MBS7205421, MyBioSource Inc., San Diego, CA, USA) for samples from mice, following manufacturer’s indications.

Techniques: Expressing, Quantitative RT-PCR, Gene Expression, Staining, Control, Positive Control, Derivative Assay, Cell Culture

Journal: Biomarker Research

Article Title: Circulating bone morphogenetic protein 8A is a novel biomarker to predict advanced liver fibrosis

doi: 10.1186/s40364-023-00489-2

Figure Lengend Snippet: Circulating BMP8A levels are increased in BDL mice. A Serum levels of BMP8A determined by ELISA. Data are expressed as pg/ml and presented as mean ± SEM. B and C Correlation of matched serum BMP8A levels with hepatic Bmp8a mRNA expression and fibrosis stage, respectively. Experimental conditions: mice with either BDL or sham operation and sacrificed 28 days after operation ( N = 7 animals per group). BDL, bile duct ligation. ** p < 0.01, BDL vs. Sham

Article Snippet: BMP8A concentration in serum samples was determined using the human BMP8A ELISA kit (CSB-EL002745HU, Cusabio Technology LLC, Hubei, China) for human samples and mouse BMP8A ELISA kit (MBS7205421, MyBioSource Inc., San Diego, CA, USA) for samples from mice, following manufacturer’s indications.

Techniques: Enzyme-linked Immunosorbent Assay, Expressing, Ligation

Journal: Biomarker Research

Article Title: Circulating bone morphogenetic protein 8A is a novel biomarker to predict advanced liver fibrosis

doi: 10.1186/s40364-023-00489-2

Figure Lengend Snippet: Increased serum BMP8A levels in NASH patients with advanced fibrosis. A Serum levels of BMP8A determined by ELISA. Data are expressed as pg/ml and presented as mean ± SD. B Correlation in the study population of matched serum BMP8A levels with fibrosis stage. C AUROC of BMP8A univariate analysis to predict advanced fibrosis (F3-F4). D AUROC of multivariate analysis. Study population: 85 NASH patients, 52 with non or mild fibrosis (F0-F2) and 33 with advanced fibrosis (F3-F4), and 36 subjects with normal liver. NASH, nonalcoholic steatohepatitis. AUROC, area under the ROC curve. * p < 0.05, ** p < 0.01 and *** p < 0.005, F3-4 vs. F0-2 or NL

Article Snippet: BMP8A concentration in serum samples was determined using the human BMP8A ELISA kit (CSB-EL002745HU, Cusabio Technology LLC, Hubei, China) for human samples and mouse BMP8A ELISA kit (MBS7205421, MyBioSource Inc., San Diego, CA, USA) for samples from mice, following manufacturer’s indications.

Techniques: Enzyme-linked Immunosorbent Assay

Journal: Biomarker Research

Article Title: Circulating bone morphogenetic protein 8A is a novel biomarker to predict advanced liver fibrosis

doi: 10.1186/s40364-023-00489-2

Figure Lengend Snippet: Univariate and multivariate analysis of the independent variables associated with advanced fibrosis in the study population

Article Snippet: BMP8A concentration in serum samples was determined using the human BMP8A ELISA kit (CSB-EL002745HU, Cusabio Technology LLC, Hubei, China) for human samples and mouse BMP8A ELISA kit (MBS7205421, MyBioSource Inc., San Diego, CA, USA) for samples from mice, following manufacturer’s indications.

Techniques:

Journal: Biomarker Research

Article Title: Circulating bone morphogenetic protein 8A is a novel biomarker to predict advanced liver fibrosis

doi: 10.1186/s40364-023-00489-2

Figure Lengend Snippet: Increased hepatic Bmp8a expression in BDL mice. A Representative images of H&E and Sirius Red staining. Evaluation of the fibrosis stage (upper panel) and quantification of Sirius Red expressed as % of stained area (lower panel). B Hepatic mRNA levels of Col1a1, Acta2 and Serpin1 determined by RT-qPCR and normalized to 36b4 gene expression. C Hepatic mRNA levels of Bmp8a determined by RT-qPCR and normalized to 36b4 gene expression. D , E , F and G Correlation of matched Bmp8a mRNA expression with fibrosis stage, Col1a1, Acta2 and Serpin1 mRNA expression, respectively. Experimental conditions: mice with either BDL or sham operation and sacrificed 28 days after operation ( N = 7 animals per group). BDL, bile duct ligation. Data are expressed as fold increase relative to control condition (sham group, 1) and presented as mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.005 and **** p < 0.0001, BDL vs. Sham

Article Snippet: BMP8A concentration in serum samples was determined using the human BMP8A ELISA kit (CSB-EL002745HU, Cusabio Technology LLC, Hubei, China) for human samples and mouse BMP8A ELISA kit (MBS7205421, MyBioSource Inc., San Diego, CA, USA) for samples from mice, following manufacturer’s indications.

Techniques: Expressing, Staining, Quantitative RT-PCR, Gene Expression, Ligation, Control

Journal: Biomarker Research

Article Title: Circulating bone morphogenetic protein 8A is a novel biomarker to predict advanced liver fibrosis

doi: 10.1186/s40364-023-00489-2

Figure Lengend Snippet: Hepatic Bmp8a expression is upregulated in NAFLD mice. A Representative images of H&E and Sirius Red staining. NAFLD activity score evaluation (upper panel) and quantification of Sirius Red expressed as % of stained area (lower panel). B Hepatic mRNA levels of Col1a1 and Serpin1 determined by RT-qPCR and normalized to 36b4 gene expression. C Hepatic mRNA levels of Bmp8a determined by RT-qPCR and normalized to 36b4 gene expression. D , E , F and G Correlation of matched Bmp8a mRNA expression with NAFLD activity score, fibrosis stage, Col1a1 and Serpin1 mRNA expression, respectively. Experimental conditions: mice fed with HFD or CHD (control group) for 16 weeks ( N = 5 animals per group). NAFLD, nonalcoholic fatty liver disease. Data are expressed as fold increase relative to control condition (CHD group, 1) and presented as mean ± SEM. * p < 0.05, ** p < 0.01 and *** p < 0.005, HFD vs. CHD

Article Snippet: BMP8A concentration in serum samples was determined using the human BMP8A ELISA kit (CSB-EL002745HU, Cusabio Technology LLC, Hubei, China) for human samples and mouse BMP8A ELISA kit (MBS7205421, MyBioSource Inc., San Diego, CA, USA) for samples from mice, following manufacturer’s indications.

Techniques: Expressing, Staining, Activity Assay, Quantitative RT-PCR, Gene Expression, Control

Journal: Biomarker Research

Article Title: Circulating bone morphogenetic protein 8A is a novel biomarker to predict advanced liver fibrosis

doi: 10.1186/s40364-023-00489-2

Figure Lengend Snippet: TGFβ induces BMP8A expression and secretion in LX2 HSCs and in Huh7 cells. A Representative phase-contrast images. B mRNA levels of COL1A1 and TGFB1 determined by RT-qPCR and normalized to 36B4 gene expression. C Representative blot of cell lysates with αSMA and COL1A1 antibodies. Ponceau staining as loading control. D Representative phase-contrast images. E mRNA levels of BMP8a determined by RT-qPCR and normalized to 36B4 gene expression. F Representative blot of CM with BMP8A antibody. Ponceau staining as loading control. As positive control ( +), HEK293 whole cell lysate was used. Experimental conditions: LX2 or Huh7 cells treated with TGFβ 10 ng/ml for 24 h ( n ≥ 3 independent experiments performed by duplicate). Huh7, human hepatocyte-derived cell line. LX2, human HSC line. CM, cultured media. Data are expressed as fold increase relative to control condition (C, 1) and presented as mean ± SEM. * p < 0.05, ** p < 0.01 and **** p < 0.0001 TGFβ vs. C

Article Snippet: BMP8A concentration in serum samples was determined using the human BMP8A ELISA kit (CSB-EL002745HU, Cusabio Technology LLC, Hubei, China) for human samples and mouse BMP8A ELISA kit (MBS7205421, MyBioSource Inc., San Diego, CA, USA) for samples from mice, following manufacturer’s indications.

Techniques: Expressing, Quantitative RT-PCR, Gene Expression, Staining, Control, Positive Control, Derivative Assay, Cell Culture

Journal: Biomarker Research

Article Title: Circulating bone morphogenetic protein 8A is a novel biomarker to predict advanced liver fibrosis

doi: 10.1186/s40364-023-00489-2

Figure Lengend Snippet: Circulating BMP8A levels are increased in BDL mice. A Serum levels of BMP8A determined by ELISA. Data are expressed as pg/ml and presented as mean ± SEM. B and C Correlation of matched serum BMP8A levels with hepatic Bmp8a mRNA expression and fibrosis stage, respectively. Experimental conditions: mice with either BDL or sham operation and sacrificed 28 days after operation ( N = 7 animals per group). BDL, bile duct ligation. ** p < 0.01, BDL vs. Sham

Article Snippet: BMP8A concentration in serum samples was determined using the human BMP8A ELISA kit (CSB-EL002745HU, Cusabio Technology LLC, Hubei, China) for human samples and mouse BMP8A ELISA kit (MBS7205421, MyBioSource Inc., San Diego, CA, USA) for samples from mice, following manufacturer’s indications.

Techniques: Enzyme-linked Immunosorbent Assay, Expressing, Ligation

Journal: Biomarker Research

Article Title: Circulating bone morphogenetic protein 8A is a novel biomarker to predict advanced liver fibrosis

doi: 10.1186/s40364-023-00489-2

Figure Lengend Snippet: Increased serum BMP8A levels in NASH patients with advanced fibrosis. A Serum levels of BMP8A determined by ELISA. Data are expressed as pg/ml and presented as mean ± SD. B Correlation in the study population of matched serum BMP8A levels with fibrosis stage. C AUROC of BMP8A univariate analysis to predict advanced fibrosis (F3-F4). D AUROC of multivariate analysis. Study population: 85 NASH patients, 52 with non or mild fibrosis (F0-F2) and 33 with advanced fibrosis (F3-F4), and 36 subjects with normal liver. NASH, nonalcoholic steatohepatitis. AUROC, area under the ROC curve. * p < 0.05, ** p < 0.01 and *** p < 0.005, F3-4 vs. F0-2 or NL

Article Snippet: BMP8A concentration in serum samples was determined using the human BMP8A ELISA kit (CSB-EL002745HU, Cusabio Technology LLC, Hubei, China) for human samples and mouse BMP8A ELISA kit (MBS7205421, MyBioSource Inc., San Diego, CA, USA) for samples from mice, following manufacturer’s indications.

Techniques: Enzyme-linked Immunosorbent Assay

Journal: Biomarker Research

Article Title: Circulating bone morphogenetic protein 8A is a novel biomarker to predict advanced liver fibrosis

doi: 10.1186/s40364-023-00489-2

Figure Lengend Snippet: Univariate and multivariate analysis of the independent variables associated with advanced fibrosis in the study population

Article Snippet: BMP8A concentration in serum samples was determined using the human BMP8A ELISA kit (CSB-EL002745HU, Cusabio Technology LLC, Hubei, China) for human samples and mouse BMP8A ELISA kit (MBS7205421, MyBioSource Inc., San Diego, CA, USA) for samples from mice, following manufacturer’s indications.

Techniques:

Journal: Cancer Science

Article Title: BMP8A promotes survival and drug resistance via Nrf2/TRIM24 signaling pathway in clear cell renal cell carcinoma

doi: 10.1111/cas.14376

Figure Lengend Snippet: BMP8A promoted clear cell renal cell carcinoma (ccRCC) proliferation and chemoresistance and inhibited apoptosis. A, BMP8A expression levels in the RCC cell lines compared with that in the human renal tubular epithelial cell line. B, Detection of BMP8A expression in 7 cell lines by ELISA. C, The tumor sections were subjected to IHC staining using antibodies against BMP8A and p‐SMAD1/5/9. D, Using CCK‐8 assays to detect cell proliferation after different treatments. E, CCK‐8 assays to detect the effects of different concentrations of BMP8A on cell proliferation. F, Detection of si‐BMP8A/si‐Ctl clone formation assays. G, Hoechst staining assay performed in ACHN and 786‐O cells with si‐BMP8A/si‐Ctl. H, The IC50 values of As 2 O 3 were determined by CCK‐8 assay in 786‐O cells. I, Apoptosis levels revealed by casp.3/7 activity assay followed with the indicated treatments in 786‐O and ACHN cells. The data represent the mean ± SD of three replicates. * P < 0.05, ** P < 0.01, *** P < 0.001

Article Snippet: BMP8A level in the culture media was measured using an ELISA Kit (R&D Systems).

Techniques: Expressing, Enzyme-linked Immunosorbent Assay, Immunohistochemistry, CCK-8 Assay, Staining, Activity Assay